References
- Swahn ML, Bygdeman M. Medical methods to terminate pregnancy. In: Baillière’s Clinical Obstetrics and Gynaecology (Volume 4). Medical Induction of Abortion. Bygdeman M (Ed.). Bailliére Tindall, London, UK, 292–306 (1990).
- Kovacs L, Sas M, Resch BA et al. Termination of pregnancy by RU 486 – an antiprogestational compound. Contraception29, 399–410 (1984).
- Shoupe D, Mishell MR Jr, Brenner PF, Spitz IM. Pregnancy termination with a high and medium dosage of RU 486. Contraception33, 455–461 (1986).
- Bygdeman M, Swahn ML. Progesterone receptor blockage – effect on uterine contractility and early pregnancy. Contraception32, 45–51 (1985).
- Wiebe E, Dunn S, Guilbert E, Jacot F, Lustig L. Comparison of abortions induced by methotrexate or mifepristone followed by misoprostol. Obstet. Gynecol.99, 813–819 (2002).
- Ferris LE, Basinski AS. Medical abortion: what does the research tell us? Can. Med. Assoc. J.154, 185–187 (1996).
- Henshaw RC, Naji SA, Russell I, Templeton AA. Comparison of medical abortion with surgical vacuum aspiration: women’s preferences and acceptability of treatment. Br. Med. J.307, 714–717 (1993).
- Winikoff B. Acceptability of medical abortion in early pregnancy. Fam. Plann. Perspect.27, 142–148 (1995).
- Van Look PFA, Bydgeman M. Antiprogestational steroids: a new dimension in human fertility control. Reprod. Bio. Rev. (Oxf.)11, 1–60 (1989).
- Birgerson L, Olund A, Odlind V, Somell C. Termination of early human pregnancy with epostane. Contraception35, 111–120 (1987).
- Le Roux PA, van der Spuy ZM. Labor induction abortion utilizing trilostane, a 3b-hydroxysteroid dehydrogenase inhibitor. Contraception71, 343–347 (2005).
- Komanicky P, Spark RF, Melby JC. Treatment of Cushing’s syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis. J. Clin. Endocrinol. Metabol.47, 1042–1051 (1978).
- Swahn ML, Kovacs L, Cekan SZ, Aedo AR, Westlund P. Termination of early pregnancy with ZK 98,734: pharmacokinetic behavior and clinical effect. Hum. Reprod.9, 57–63 (1994).
- Heikinheimo O, Kekkonen R. Dose-response relationship of RU 486. Ann. Med.25, 71–76 (1993).
- Baird DT. Mode of action of medical methods of abortion. J. Am. Med. Womens Assoc.55, 121–126 (2000).
- World Health Organization Task Force on Post-Ovulatory Methods for Fertility Regulation. Termination of pregnancy with reduced doses of mifepristone. Br. Med. J.30, 532–537 (1993).
- World Health Organization Task Force on Post-Ovulatory Methods for Fertility Regulation. Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomized trial. Br. J. Obstet. Gynaecol.107, 524–530 (2000).
- World Health Organization Task Force on Post-Ovulatory Methods for Fertility Regulation. Medical abortion at 57 to 63 days gestation with a lower dose of mifepristone and gemeprost. A randomized controlled trial. Acta Obstet. Gynecol. Scand.80, 447–451 (2001).
- Kulier R, Gülmezoglu AM, Hofmeyr GJ, Cheng LN, Campana A. Medical methods for first trimester abortion. Cochrane Database Syst. Rev.1, CD002855 (2006).
- World Health Organization Task Force on Post-Ovulatory Methods for Fertility Regulation. Lowering the doses of mifepristone and gemeprost for early abortion: a randomized controlled trial. Br. J. Obstet. Gynaecol.108, 738–742 (2001).
- Collins PW. Misoprostol: discovery, development and clinical applications. Med. Res. Rev.10, 149–172 (1990).
- Kotsonis FN, Dodd DC, Regnier B, Kohn FE. Preclinical toxicology profile of misoprostol. Dig. Dis. Sci.11(Suppl. 11), 142S–146S (1985).
- Spitz IM, Bardin CW, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N. Engl. J. Med.338, 1241–1247 (1998).
- El-Refaey H, Rajasekar D, Abdalla M, Calder L, Templeton A. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol. N. Engl. J. Med.332, 983–987 (1995).
- von Hertzen H, Honkanen H, Piaggio G et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. I: efficacy. Br. J. Obstet. Gynaecol.110, 808–818 (2003).
- Honkanen H, Piaggio G, von Hertzen H et al. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion. II: side effects and women's perceptions. Br. J. Obstet. Gynaecol.111, 715–725 (2004).
- Tang OS, Schweer H, Seyberth HW, Lee SW, Ho PC. Pharmacokinetics of different routes of administration of misoprostol. Hum. Reprod.17, 332–336 (2002).
- Ngai SW, Tang OS, Chan YM, Ho PC. Vaginal misoprostol alone for medical abortion up to 9 weeks of gestation: efficacy and acceptability. Hum. Reprod.15, 1159–1162 (2000).
- Aronsson A, Bygdeman M, Gemzell-Danielsson K. Effects of misoprostol on uterine contractility following different routes of administration. Hum. Reprod.19, 81–84 (2004).
- Ashok PW, Templeton A, Wagaarachchi PT, Flett GM. Factors affecting the outcome of early medical abortion: a review of 4132 consecutive cases. Br. J. Obstet. Gynaecol.109, 1281–1289 (2002).
- WHO. Safe Abortion: Technical and Policy Guidance for Health Systems. WHO, Geneva, Switzerland (2003).
- Royal College of Obstetricians and Gynaecologists. National Evidence-based Clinical Guidelines: The Care of Women Requesting Induced Abortion. Updated Guidelines. RCOG, London, UK (2004).
- Swahn ML, Bygdeman M. The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin. Br. J. Obstet. Gynaecol.95, 126–134 (1988).
- Ashok PW, Flett GM, Templeton A. Mifepristone versus vaginally administered misoprostol for cervical priming before first-trimester termination of pregnancy: a randomized, controlled study. Am. J. Obstet. Gynecol.183, 998–1002 (2000).
- Schaff EA, Fielding SL, Westhoff C et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial. JAMA284, 1948–1953 (2000).
- Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception64, 81–85 (2001).
- Davey A. Mifepristone and prostaglandin for termination of pregnancy: contraindications for use. Reasons and rationale. Contraception74, 16–20 (2006).
- Chan YF, Ho PC, Ma HK. Blood loss in termination of early pregnancy by vacuum aspiration and by combination of mifepristone and gemeprost. Contraception47, 85–95 (1993).
- Vogel D, Burkhardt T, Rentsch K et al. Misoprostol versus methylergometrine: pharmacokinetics in human milk. Am. J. Obstet. Gynecol.191, 2168–2173 (2004).
- Xu J, Chen H, Ma T, Wu X. Termination of early pregnancy in the scarred uterus with mifepristone and misoprostol. Int. J. Gynaecol. Obstet.72, 245–251 (2001).
- Ashok PW, Penney GC, Flett GMM, Templeton A. An effective regimen for early medical abortion: a report of 2000 consecutive cases. Hum. Reprod.13, 2962–2965 (1998).
- Shannon C, Brothers LP, Philip NM, Winikoff B. Infection after medical abortion: a review of the literature. Contraception70, 183–190 (2004).
- Fischer M, Bhatnagar J, Guarner J et al. Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion. N. Engl. J. Med.353, 2352–2360 (2005).
- Gary MM, Harrison DJ. Analysis of severe adverse events related to the use of mifepristone as an abortifacient. Ann. Pharmacother.40, 191–197 (2006).
- Sitruk-Ware R, Davey A, Sakiz E. Fetal malformation and failed medical termination of pregnancy. Lancet352, 323 (1998).
- Elger W, Neef G, Ottow E et al. Studies on interactions of antiprogestins with prostaglandins and sex hormone-related agents at the myometrial level in pregnant guinea pigs. In: Hormone Antagonists for Fertility Regulation. Puri CP, Van Look PFA (Eds). Good Print Publishers, Bombay, India, 105–121 (1995).